<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059978</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01217; qu18Ruppen3</org_study_id>
    <nct_id>NCT04059978</nct_id>
  </id_info>
  <brief_title>Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults</brief_title>
  <acronym>CANAB II</acronym>
  <official_title>Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate
      the effect of cannabidiol (CBD) on remifentanil-induced hyperalgesia in healthy volunteers in
      a well-established acute pain model. Participants are randomized according to the order of
      the two treatments (CBD + Remifentanil or Placebo + Remifentanil).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opioid-induced hyperalgesia (OIH) is a clinically often neglected, but well described
      phenomenon. OIH could also be shown for Remifentanil in an acute pain model. As CBD showed
      antihyperalgesic potential in the animal model, this brings up the question if CBD might be
      used to prevent or diminish OIH. Until today there are no studies investigating CBD as an
      adjunct to remifentanil or other opioids regarding the OIH. This is however of great clinical
      value because CBD with its possible antihyperalgesic effect on the OIH might be a worthful
      adjunct for opioid based anaesthesia and analgesia.

      Every participant will pass through two interventions with electrically induced pain (Koppert
      model). CBD will be applied orally at the beginning of the intervention. Pain, allodynia and
      hyperalgesia will be assessed and recorded every 10 min during the remifentanil infusion and
      afterwards.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hyperalgesia measured by the area under the curve (AUCHyper)</measure>
    <time_frame>from minute 100 to minute 160 after termination of remifentanil infusion</time_frame>
    <description>Change in hyperalgesia measured by the area under the curve (AUCHyper)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain response (NRS) measured by the area under the curve (AUCNRS)</measure>
    <time_frame>from minute 70 to minute 90 during remifentanil infusion</time_frame>
    <description>Change in pain response (NRS) measured by the area under the curve (AUCNRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hyperalgesia measured by the area under the curve (AUCHyper)</measure>
    <time_frame>from minute 70 to minute 90 during remifentanil infusion</time_frame>
    <description>Change in hyperalgesia measured by the area under the curve (AUCHyper)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in allodynia measured by the area under the curve (AUCAllo)</measure>
    <time_frame>from minute 70 to minute 90 during remifentanil infusion</time_frame>
    <description>Change in allodynia measured by the area under the curve (AUCAllo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain response (NRS) measured by the area under the curve (AUCNRS)</measure>
    <time_frame>from minute 100 to minute 160 after termination of remifentanil infusion</time_frame>
    <description>Change in pain response (NRS) measured by the area under the curve (AUCNRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in allodynia measured by the area under the curve (AUCAllo)</measure>
    <time_frame>from minute 100 to minute 160 after termination of remifentanil infusion</time_frame>
    <description>Change in allodynia measured by the area under the curve (AUCAllo)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Acute Nociceptive Pain</condition>
  <condition>Hyperalgesia</condition>
  <condition>Allodynia</condition>
  <condition>Opioid-induced Hyperalgesia</condition>
  <arm_group>
    <arm_group_label>CBD + Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBD 800 mg p.o. + Remifentanil 0.1 µg/kg/min i.v. for 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Remifentanil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo p.o + Remifentanil 0.1 µg/kg/min i.v. for 30 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>800mg cannabidiol, single oral dose (8 ml oily solution)</description>
    <arm_group_label>CBD + Remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo p.o, single oral dose (8 ml oily solution)</description>
    <arm_group_label>Placebo + Remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil 0.1 µg/kg/min i.v. for 30 min</description>
    <arm_group_label>CBD + Remifentanil</arm_group_label>
    <arm_group_label>Placebo + Remifentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18.5 until 25 kg/m2

          -  Able to give informed consent

        Exclusion Criteria:

          -  Regular consumption of cannabinoids or other drugs / substances

          -  Regular intake of medications potentially interfering with pain sensation (analgesics,
             antihistamines, calcium and potassium channel blockers, serotonin / noradrenaline
             reuptake inhibitors, corticosteroids)

          -  Neuropathy

          -  Chronic pain

          -  Neuromuscular disease

          -  Psychiatric disease

          -  Known or suspected kidney or liver disease

          -  Pregnancy (cf. 8.6 Trial specific preventive measures) / Lactation

          -  Allergy / hypersensitivity to cannabidiol

          -  Contraindications for Remifentanil (e.g. hypersensitivity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, University Hospital of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Schneider, MD</last_name>
    <phone>+4161 328 51 65</phone>
    <email>tobias.schneider@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wilhelm Ruppen, Prof. MD</last_name>
    <phone>+41613286496</phone>
    <email>wilhelm.ruppen@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anaesthesiology, University Hospital of Basel (USB)</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilhelm Ruppen, Prof. MD</last_name>
      <phone>+4161 328 64 96</phone>
      <email>wilhelm.ruppen@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Schneider, MD</last_name>
      <phone>+4161 328 51 65</phone>
      <email>tobias.schneider@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Dominik Dieterle</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eckhard Mauermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <keyword>Remifentanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

